The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.

Described herein are IRE1α inhibitors, compositions containing such inhibitors, and methods of treatment that include administration of such compounds. Exemplary compounds are provided throughout the application.

The invention relates to a combination comprising (3S, 11aR)—N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof and rilpivirine, along with therapeutic methods administering the same.

The invention relates to a combination comprising (3S, 11aR)—N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo [3,2-a] pyrido [1,2-d] pyrazine-8-carboxamide, or a pharmaceutically acceptable salt thereof and rilpivirine, along with therapeutic methods administering the same.

The invention provides compounds and methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits.

The invention provides compounds and methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits.

Certain embodiments are directed to methods and compositions related to delivery of therapeutic agents via syncytiotrophoblast-derived extracellular vesicles (EVs).

Provided herein are methods of treating central nervous system (CNS) disorders (e.g., Binge Eating Disorder (BED), Attention-Deficit/Hyperactivity Disorder (ADHD), etc.) with a dasotraline therapy while avoiding adverse drug interactions.

Provided herein are methods of treating central nervous system (CNS) disorders (e.g., Binge Eating Disorder (BED), Attention-Deficit/Hyperactivity Disorder (ADHD), etc.) with a dasotraline therapy while avoiding adverse drug interactions.